Objectives: Previous data from our research had shown that the novel ceragenin, CSA-13, demonstrated concentration-dependent bactericidal activity against glycopeptide-resistant Staphylococcus aureus. However, it is unknown whether CSA-13 demonstrates a similar property against Pseudomonas aeruginosa. We evaluated CSA-13 antipseudomonal activity compared with cefepime, meropenem, piperacillin/tazobactam, tobramycin and ciprofloxacin by susceptibility testing as well as in combination with cefepime, tobramycin and ciprofloxacin.
Introduction
The emergence of multidrug resistance in Pseudomonas aeruginosa and other Gram-negative pathogens is concerning and underscores the need for more therapeutic options and alternative agents. Reported rates of multidrug-resistant (MDR) P. aeruginosa have varied from 0.6% to as high as 49% depending on geographic location, study interval and type of surveillance study with their respective definitions. 1 -6 Infections with MDR P. aeruginosa are associated with considerable morbidity and mortality. Some studies have reported increased length of hospital stay and a mortality rate as high as 31.1% with MDR P. aeruginosa infections. 7 -9 This advent of MDR, especially among Gram-negative pathogens, has coincided with a renewed interest in the development of novel antimicrobial agents. The drive to produce newer agents targeting novel sites that may circumvent resistance is critical to long-term control of bacterial infection. One frequently studied target is the bacterial membrane. This is an appealing target given that most structural elements are conserved and resistance to membrane-targeting antibiotics would require major changes in the membrane structure, which may influence the permeability barrier. 10 Many agents that target the bacterial membrane are cationic, facially amphiphilic molecules including endogenous antimicrobial peptides. Unlike typical amphiphilic compounds, facially amphiphilic molecules display separate hydrophilic and hydrophobic faces. Examples of facially amphiphilic antimicrobial peptides include the magainins and the human antimicrobial peptide LL37. Most antimicrobial peptides display broad-spectrum antibacterial activity and target the bacterial membrane. However, many antimicrobial peptides are difficult to synthesize and purify due to their complexity and size. 11 In addition, antimicrobial peptides can be substrates for proteases, which limit their in vivo half-lives.
Recently, facially amphiphilic compounds designed to mimic the activities of antimicrobial peptides have been generated from a steroid scaffold. This non-peptide-based approach has yielded a class of compounds termed ceragenins with antibacterial activity comparable to that of antimicrobial peptides. 12 -14 Given that the amphiphilic properties of ceragenins and antimicrobial peptides are similar, it has been postulated that these agents share a mechanism of action including depolarization of bacterial membranes. 15 As a consequence of the bacterial membrane activity of ceragenins, they effectively permeabilize the outer membranes of Gram-negative bacteria, and thus make these organisms susceptible to hydrophobic antimicrobials. 16, 17 Many of the ceragenins reported in the literature and at recent scientific meetings display broad-spectrum antibacterial activity. Some of these agents such as CSA-13 are bactericidal at low concentrations with similar MIC and MBC values. Previous data from our research have shown that the novel ceragenin, CSA-13, is more potent than CSA-8 and demonstrates concentration-dependent activity against glycopeptide-resistant Staphylococcus aureus. 18 MIC testing against common Gramnegative aerobic and facultative bacilli, strict anaerobes such as Propionibacterium acnes and Clostridium perfringens as well as MDR S. aureus has demonstrated that CSA-13 possesses a broad spectrum of activity. 19, 20 To better understand the antibacterial activity of CSA-13 against Gram-negative bacteria, we evaluated CSA-13 against clinical isolates of P. aeruginosa, including MDR-P. aeruginosa. We also examined CSA-13 for concentration-dependent activity and potential synergy in combination with various antimicrobials. Table 1) .
Materials and methods

Bacterial strains
Antimicrobial agents
CSA-13 was synthesized and provided by one of the authors (P. B. S.). CSA-13 was synthesized from a cholic acid scaffolding technique as previously described. 
Medium
Mueller -Hinton broth (MHB; Difco Laboratories, Detroit, MI, USA) supplemented with magnesium (12.5 mg/L total concentration) and calcium (25 mg/L total concentration) (SMHB) was used for all microdilution susceptibility testing and time -kill analysis. Mueller-Hinton agar (MHA; Difco Laboratories, San Jose, CA, USA) was used for growth and to quantify colony counts.
Susceptibility testing
MICs as well as MBCs were determined by utilizing standardized broth microdilution techniques with a starting inoculum of 5 Â 10 5 cfu/mL according to CLSI guidelines and incubated for 24 h at 358C. 21 MICs were determined in duplicate, with concentrations ranging up to 256 mg/L for meropenem, cefepime, ciprofloxacin, piperacillin/tazobactam and CSA-13; and up to 32 mg/L for tobramycin.
Time -kill curve analysis
All time -kill experiments were performed in triplicate with an initial inoculum of 10 6 cfu/mL. To evaluate concentrationdependent activity, four clinical strains were exposed to CSA-13 at 0.5Â, 1Â, 2Â and 4Â the MIC. To evaluate for synergy, the same strains were exposed to CSA-13 alone and in combination with tobramycin, cefepime and ciprofloxacin at 0.5Â the MIC. Aliquots (0.1 mL) were removed from cultures at 0, 1, 4, 8 and 24 h and serially diluted in cold 0.9% sodium chloride. Synergy, Chin et al.
additive effect, antagonism and indifference were defined as .2 log kill, ,2 but .1 log kill, .1 log growth and +1 log kill, respectively. Bacterial counts were determined by spiral plating appropriate dilutions using an automatic spiral plater (WASP; DW Scientific, West Yorkshire, UK) and by counting colonies using the protocol colony counter (Synoptics Limited, Frederick, MD, USA). The lower limit of detection for colony count was 2 log 10 cfu/mL. Time -kill curves were constructed by plotting mean colony counts (log 10 cfu/mL) versus time. To eliminate antimicrobial carryover, all samples were either diluted sufficiently prior to plating or subjected to vacuum filtration with 0.9% sodium chloride if close to the MIC post-dilution.
Results
Susceptibility
Susceptibility testing of the clinical isolates (n ¼ 50) demonstrated that the MIC 50 (range) and MBC 50 (range) for CSA-13 were (mg/L) 16 (1 -32) and 16 (2 -32) ( CSA-13 synergy against P. aeruginosa
Concentration-dependent bactericidal killing
Time -kill analysis of all four strains demonstrated concentration-dependent activity. Time to 99.9% kill (detection limit) occurred by 1 h for three strains and by 4 h for one strain when the concentration tested was 4Â the MIC (Figure 1 ). At 1Â and 2Â the MIC, time to achieve 99.9% kill was by 24 and 8 h, respectively. Reduction in bacterial growth was not detected with the subinhibitory concentration of 0.5Â the MIC for two strains. Instead, regrowth occurred by 4 h in those strains.
Combination testing
The addition of cefepime and ciprofloxacin to CSA-13 demonstrated enhanced activity with the novel ceragenin. Time -kill analysis demonstrated additive effect at 24 h in two strains (711 and R1130), synergy in strain 727 and indifference in strain 316 when cefepime was combined with CSA-13. However, early synergy was detected at 4 -8 h with this combination (average log 10 cfu/mL reduction of 22.32 + 0.18, Figure 2a ). The addition of ciprofloxacin to CSA-13 demonstrated synergy at 24 h (23.31 + 1.21, Figure 2b ) in three strains (316, 711 and R1130), achieving early synergy at 4 -8 h (22.78 + 0.69) and even earlier additive effect at 1 -4 h (21.72 + 0.34, Figure 2c ). Time -kill analysis showed no improvement in kill at 24 h (0.51 + 0.56) for two of the four strains (R1130 and 316) when tested with CSA-13 in combination with tobramycin ( Figure 2d ). However, antagonism was detected at 24 h (þ1.41 + 0.31) in one strain (727), whereas in another strain (711), synergy was detected at 24 h (22.06 + 0.52).
Discussion
Ceragenins are unique, small molecular weight compounds that have potent bactericidal activity against both Gram-negative and -positive bacteria. Previous data have suggested potent activity of CSA-13 against Gram-positive pathogens such as methicillinresistant S. aureus and glycopeptide-intermediate and -resistant S. aureus. However, ceragenin data on Gram-negative organisms are limited. Although a collection of Gram-negative pathogens including Acinetobacter spp., Escherichia coli and Klebsiella pneumoniae were evaluated elsewhere, the number of organisms tested for susceptibility for each species was 10. Here, we report an MIC 50 of 16 mg/L for 50 P. aeruginosa strains, and an MIC 50 of 8 mg/L for a subset of carbapenem-resistant isolates. This is similar to previous data as reported by Savage who observed an MIC 50 of 8 mg/L in two separate small studies. 19, 20 Indeed, the CSA-13 antimicrobial activity is lower in this population of Gram-negative pathogens compared with results previously reported on Gram-positive organisms. This could be attributed to a high content of phosphatidylethanolamine and may inhibit CSA-13 from inducing leakage of aqueous contents from phosphatidylethanolamine-rich liposomes.
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Our study also showed that CSA-13 has an MIC 50 /MBC 50 ratio of 1, suggesting that the bactericidal activity is close to the inhibitory concentration. Indeed, varying CSA-13 concentrations at, below and above the MIC demonstrated concentrationdependent antimicrobial activity, similar to previous published data on glycopeptide-resistant S. aureus. These findings suggest that CSA-13 exhibits concentration-dependent activity against both Gram-positive and -negative organisms. In addition, CSA-13 can be used to enhance other antimicrobial agents against P. aeruginosa. Combination time -kill studies against four clinical strains, three of which were meropenem intermediate to resistant, demonstrated synergy or additive effect with the addition of cefepime or ciprofloxacin, achieving early synergy or additive effect at 4 -8 and 1 -4 h, respectively. However, we were only able to demonstrate synergy with the combination of tobramycin and CSA-13 in one strain (711). Evaluating synergy in a time -kill assay would be technically difficult in this case given that the tobramycin MICs for three of the strains were 1 mg/L, with the exception of strain 711 which has an MIC of 4. The addition of CSA-13 may have enhanced the bacterial activity of tobramycin against this relatively resistant strain and thus perhaps explains the observed synergy. In addition, tobramycin has been used as a synergistic agent against Pseudomonas in vitro and enhanced activity is usually best observed in b-lactam combinations. 23, 24 It is possible that two synergistic agents may counteract each other. However, more studies with a greater range of clinical isolates would be necessary to establish that theory.
Previous preliminary data have studied the potential synergy of a similar ceragenin, CSA-8 (with less activity than CSA-13) in combination with rifampicin against tobramycin-resistant P. aeruginosa. 25 The authors concluded that CSA-8 and CSA-13 can permeabilize the outer membrane of Gram-negative organisms thus resulting in sensitization to antimicrobials. This mechanism may explain the synergy that we observed with cefepime and ciprofloxacin in combination with CSA-13.
Our findings support CSA-13 as a potential agent against Gram-negative organisms. CSA-13 demonstrates synergy with cefepime and ciprofloxacin against P. aeruginosa. Further studies with other compounds in combination with CSA-13 as well as on other Gram-negative pathogens such as Acinetobacter spp., E. coli and K. pneumoniae should also be explored.
